Angiographic assessment of corneal neovessels
CoNV is always pathological because the cornea in its physiological state is avascular. In a state of health, an equilibrium of proangiogenic and antiangiogenic factors prevents the formation of CoNV. CoNV forms as a response to injury and is characterised by abnormal vessel architecture affecting predominantly interendothelial cell tight junctions and pericyte ensheathment, associated with transvascular exudation in both immature and stabilised states.11 12
An experiment by Sivak et al identified two phases of corneal angiogenesis.13 Initial angiogenesis is due to increased levels of vascular endothelial growth factor (VEGF), which is directly secreted from corneal repair epithelial cells. Subsequent angiogenesis occurs due to the inflammatory cascade initiated by proinflammatory cytokines released by the same cells. While the initial stimulus is therefore VEGF-dependant and independent from inflammation, it is only later (after day 3) that the inflammatory cascade evolves and causes increased angiogenesis. VEGF-A has been identified as the key member of the family. It interacts with the greatest affinity to VEGF receptors 1 and 2, which are expressed on limbal vascular endothelial cells and when bind to VEGF-A form a proangiogenic stimulant, promoting both corneal blood and lympohangiogenesis.11 A soluble (non-membrane associated) form of VEGF receptor 1 is situated in the extracellular space of the cornea. It is able to bind to VEGF-A and form an antiangiogenic stimulant, acting as a buffer system to maintain corneal avascularity. It has been shown, that VEGF receptor 1 expression is selectively suppressed in corneal epithelial cells in herpes simplex keratitis, which explains rapid and aggressive corneal angiogenesis observed especially in this type of infectious keratitis.14
Despite the detrimental effect of CoNV on corneal clarity and surface regularity, it has been observed that clinical stabilisation of herpes simplex keratitis correlates with the time of vessel stabilisation, suggesting a role of angiogenesis in the immune response, resolution of infectious keratitis and subsequent corneal healing. Maruyama et al showed that macrophages in the bloodstream infiltrate areas of inflammation and become activated, secreting TNF-alpha and VEGF, thereby inducing haemangiogenesis and lymphangiogenesis.15 It has also been determined that these blood and lymphatic vessels are closely related to the process of wound healing and the resolution of bacterial keratitis16 and that they decrease oedema and inflammation in bacterial keratitis.17 18 Despite these positive effects, the presence of CoNV in a recipient corneal bed is an important risk factor for corneal allograft rejection.12 The extent of vascularisation of the recipient cornea at the time of corneal transplantation correlates strongly with the risk of graft rejection and failure. Similarly, vascularisation of the graft in the postoperative period is also associated with an increased risk of graft failure.19
While the clinical assessment of patients undergoing keratoplasty focuses mainly on the presence of corneal haematic vessels, it is now known, that coexistent, but biomicroscopically invisible, corneal lymphatic vessels are in fact the principal mediators of corneal graft rejection.20 Dierich et al where able to show in a murine model, that the risk of corneal graft rejection in both haemvascularised and avascular corneal beds was not significantly different, while risk was significantly increased in graft beds with both blood and lymphatic vascularisation. In a similar model Hos and coworkers showed that the blockade of corneal lymphangiogenesis using VEGFR-tyrosine kinase inhibitor ZK 261991 resulted in improved graft survival after corneal transplantation. Consequently, clinically feasible lymphangioregressive approaches have successfully been implemented for the preconditioning treatment of corneal graft beds to decrease corneal lymphatic vessels, including fine-needle diathermy,6 21 VEGF inhibition,22 23 photodynamic therapy17 24 and corneal collagen cross-linking.25 26 While these clinical measures may reduce the risk of corneal graft rejection in high-risk keratoplasty, it remains clinically impossible to verify individual lymphangioregressive treatment efficacy due to a lack of feasible imaging methods to visualise corneal lymphatic vessels.
A thorough understanding of the time course of corneal blood and lymphatic angiogenesis or angioregression is therefore clinically important. While both corneal blood and lymphatic vessels contemporaneously grow onto the cornea following an inciting event, subsequent vessel regression is different in that lymphatic vessels regress more rapidly over time. Cursiefen et al have shown that lymphatic vessels are present in all excised vascularised corneal buttons with CoNV aged less than 3 months, while no lymphatic vessels were detectable on immunohistochemical analysis in corneas with neovascularisation aged more than 60 months.27 So age and the clinical stage of corneal haematic neovessels can serve as an indirect indicator of lymphatic vessel presence in a future graft bed.
However, precise clinical staging of CoNV from appearance is difficult. A five-point staging scale has been proposed, but the authors acknowledge that the differentiation of stages 2–4 is clinically difficult and not reproducible.28
Intravenous angiography allows the objective quantitative and functional assessment of CoNV. ICGA reliably depicts CoNV and any change of area of vascularisation, even in the presence of corneal opacification.3 ICGA enables the identification of corneal feeder vessels for subsequent angiography-guided selective arteriolar fine-needle diathermy.6 Fluorescein dye, on the other hand, readily leaks from vasculature. The time to leakage and the extent of leakage have been shown to correlate with vessel maturity and disease activity in both corneal and conjunctival inflammatory disease.4 7 More recently, Palme et al were able to demonstrate late leakage of ICG dye from active but not inactive or regressed CoNV, adding ICGA as a feasible tool to objectively stage CoNV.5 ICG leakage from young active vessels was characterised by a more focal leakage pattern compared with fluorescein leakage, presumable at locations of active angiogenesis with endothelial fenestrations large enough allow transvascular leakage of albumin-bound ICG.29
Of interest, ICG leakage was observed only in CoNV aged less than 3 months, matching the time of lymphatic vessel regression in vascularised corneas.
These data suggest that the presence of ICG leakage from CoNV is associated with vessel immaturity and the presence corneal lymphatic vessels. Preliminary data analysis of an ongoing study confirmed a significant correlation between ICG leakage in vascularised corneas of patients undergoing keratoplasty and the presence of lymphatic vessels, suggesting ICG leakage as an indirect indicator for risk assessment of vascularised corneal graft beds.30
More recently optical coherence tomography (OCT) technology has been used to assess CoNV.31 OCT angiography (OCTA) offers a fast and non-invasive approach to depict OS vasculature and yields excellent depth information even in the presence of scars or other corneal opacification. As a continuously evolving OCT application, however, it is still currently limited by severe artefacts, small field-width, and inferior overall image quality compared with ICGA.32 Additionally, it lacks information on flow direction for planning of selective afferent fine-needle diathermy, and any functional information on maturity and vessel activity. While OCTA currently is not an alternative to intravenous angiography, fast technological progress and the integration of deep learning algorithms into the analysis of vascular networks is expected to widen its applicability for OS angiography in the future.